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INTRODUCTION
In this paper, we have reviewed current problems in tumor immunology with
regard to melanoma and report our studies of a small series of patients with mela-
noma and other malignancies. A humoral response to malignant melanoma has
been well established by the immunofluorescence test (1-5). Cross-reacting cyto-
plasmic antigens were detected as were cross-reacting and individually specific
membrane tumor-associated antigens (5, 6).
Cell-mediated immunity has been shown in patients with progressively growing
tumors and in patients clinically free of disease by in vitro techniques (7-12). Cyto-
toxicity of peripheral lymphocytes was observed in both the autochthonous and
allogeneic systems (7, 8, 12). Also, lymphocyte cytotoxicity has been observed
to be abrogated by serum-mediated factors in a large number of patients with
malignant melanoma (13).
In studying cell-mediated immunity in human malignant melanoma, deVries
(12) observed in several patients that lymphocytes appeared to lose their capacity
for killing melanoma target cells in the absence of systemic treatment. They did
not observe a correlation between the presence of immune lymphocytes and the
clinical stage of disease.
After demonstration of humoral antibodies to surface and intracellular antigens
by immunofluorescence tests (5), we tried to detect a humoral response to soluble
extracts of melanoma tumors by gel diffusion (17). While unable to demonstrate
tumor-specific antibodies in sera by immunodiffusion, the extracts prepared as a
source of antigen were found to contain substantial amounts of immunoglobulins.
Further studies, utilizing antisera to specific human immunoglobulins, revealed that
a majority of fluorocarbon-prepared extracts of melanoma tumor and all extracts
prepared by the freeze-thaw method contained IgG. A lesser but substantial num-
ber also contained IgA. When compared by quantitative radial immunodiffusion
with similarly prepared normal tissue extracts, it was found that the tumor extracts
had higher concentrations of these immunoglobulins (unpublished data).
Next, attempts were made to elute the immunoglobulins from the surface of
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live melanoma tumor cells. One such eluate was prepared from a recurrent tumor
excised from a patient who had undergone long-term active immunotherapy.
The effects of fluorocarbon extracts, freeze-thaw extracts, and eluates on the
growth of melanoma cells propagated in vitro were then studied. Fluorocarbon
extracts and eluates were also tested for their ability to block the cytotoxic action
of sensitized lymphocytes by in vitro cell-mediated immunity tests.
Humoral and cell-mediated immunity studies were carried out utilizing serial
serum samples from two patients who were undergoing long-term immunotherapy.
The sera of these two patients were first studied for tumor antibody by gel diffu-
sion (Ouchterlony method) using fluorocarbon and freeze-thaw tumor extracts,
similarly prepared extracts of tissue-cultured melanoma cells, and extracts of ho-
mologous tumor vaccines as the source of antigen.
The serial serum samples were tested for complement-fixing antibody against
the soluble antigen preparations, utilizing guinea pig serum as the source of
complement.
The immunotherapy-patient sera were finally tested for complement-dependent
cytotoxic antibody to cultured melanoma target cells, using rabbit complement
diluted with human umbilical cord serum.
For possible correlation of immunological parameters with tumor growth and/or
recurrence of disease (15), the immunotherapy patient sera were tested for L-3,4-
dihydroxyphenylalanine (dopa) oxidase activity, anticipating that this enzyme may
reflect metabolic functions of malignant melanoma in vivo.
MATERIALS AND METHODS
Serum and tumor collection. Blood collected by venipuncture was allowed to
clot at room temperature and the serum decanted following centrifugation. The
serial blood samples from the immunotherapy patients were obtained just before
each injection of vaccine. Normal control sera were obtained from healthy hospital
employees and staff who had no history of transfusions or pregnancies.
Melanoma tumors were obtained from fresh surgical specimens and immediately
processed.
Specific immunoglobulin antisera were obtained from Hyland, Travenol Division.
Extract and eluate preparation. Extracts of tumor and normal tissue were pre-
pared by homogenization with a VirTis '45' homogenizer equipped with an ice
bath. After sedimentation of the debris, supernatant fluids were extracted five times
with % volumes of Genetron 113, as previously described (17).
Freeze-thaw extracts were prepared by homogenization of 20% (w/v) suspen-
sions (as described above) followed by freezing in an acetone/dry ice bath and
thawing in water at 370C. Following centrifugation at 20,000 rpm for 30 min at
4CC, the debris was discarded.
Eluates were prepared by teasing excised tumors into a single cell suspension
in phosphate buffer with sterile forceps and scalpel. The cell suspension was then
put through a 200-mesh wire screen to retain the fibrous elements and remaining
clumps. The cell suspension was washed briefly in several volumes of phosphate
buffer, pH 7.5, centrifuged to pellet the cells, and the supernatant discarded. The
cells were resuspended in 100 vol of buffer and washed for 1 hr at 4CC. with con-
tinuous stirring. After the extended wash, the cells were resuspended in 10 vol
of cold glycine buffer at pH 2.4 and gently agitated for 30 min at 40C, the super-
natant removed, and the pH immediately adjusted to neutral using 1 N NaOH.
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The supernatant was then dialyzed against phosphate buffer, pH 7.5, and concen-
trated to original packed-cell volume by Amicon diafiltration equipped with an
XM-100 (retaining molecules above 100,000 molecular weight) membrane. The
eluates were then tested by gel diffusion for immunoglobulin content using specific
immunoglobulin antisera and used as the source of antibody in the lymphocyte
microcytotoxicity test.
Complement fixation tests. Complement fixation studies were carried out accord-
ing to the microtiter method outlined by Sever (18) on the sera of the immuno-
therapy patients. Individual melanoma tumor extracts, prepared by fluorocarbon
extraction as previously described, and pooled tumor extracts were used as the
source of antigen. Similarly prepared extracts of normal tissues and of human sar-
comas were used as controls. Guinea pig serum obtained from Hyland, Travenol
Division, was used as the source of complement.
Complement-dependent cytotoxicity tests. Serum-mediated, complement-depen-
dent cytotoxicity studies were conducted similarly to the test outlined by Wood
and Morton (14), on the immunotherapy-patient sera and a battery of normal
control sera. Human umbilical cord serum, used to dilute rabbit complement 1: 1,
was obtained from Cordis Laboratories, Miami, Florida, and by local collection.
Cultured melanoma cells, used as target cells, were incubated with test serum for
1 hr at 370C. Complement was then added to the plates and incubated for an
additional 2 hr at 370C. Complement and serum were then removed, replaced with
fresh media, and the plates incubated overnight at 370C. The target cells were
then washed with Hanks BSS buffer, air-dried, stained with Giemsa, and the re-
maining cells scored microscopically.
Vaccine preparation. Vaccines used in immunotherapy were made by preparing
a single cell suspension of melanoma tumor in Hanks BSS. The cells were irradi-
ated with 10,000 r to render them nonreproductive. The cell suspension was ad-
justed to contain 1 X 10' viable cells/ml and aliquotted in 1 ml ampules. The
ampules were stored at -700C following tests for sterility and reproductivity.
Immunization was carried out by intradermal injection of 1 ml of cells at regular
intervals.
Lymphocyte isolation. Forty milliliters of heparinized peripheral blood was
left at room temperature for 1-2 hr to allow the red cells to settle. The supernatant
was then decanted, the cells sedimented by a low-speed spin, washed in Hanks
BSS, centrifuged, and resuspended in media. This suspension was placed on a 4-in.
column of beads and incubated in a water bath at 370C for 10 min. The lympho-
cytes were flushed from the column with Eagles' medium containing 10% fetal
calf serum. After counting, the cells were resuspended in an appropriate amount
of Eagles' medium to give a ratio of from 500 to 1,000 lymphocytes per target
cell.
In vitro lymphocyte cytotoxicity tests. SH-1 cells, established by Giovanella et
al. (21) from a malignant melanoma tumor and shown by previous tests to possess
antigenicity to sensitized lymphocytes from melanoma patients, were used routinely
in these tests. Line LeCA, strain 26-5 human melanoma cells, established in this
laboratory 6 years ago and shown to be sensitive to the cytotoxic action of lympho-
cytes, were also used routinely. Both human melanoma cell lines have been shown
to have similar sensitivities to cytotoxic action of donor lymphocytes.
The lymphocyte microcytotoxicity procedures used in the tests have been re-
ported (8, 20). The sera and eluates to be tested for blocking activity were used
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undiluted and were inactivated at 560C for 30 min. Following incubation with tar-
get cells for 1 hr at 370C, they were poured off, and the lymphocyte suspension
was then added. After incubation for 48 hr at 370C, the lymphocytes and media
were removed, and the plates washed and air-dried. The cells remaining in the
plates were fixed with methanol, stained with Giemsa, and scored by microscopy.
Serum enzyme studies. Serum proteins were separated by polyacrylamide disc
electrophoresis as described by Davis (19). For each column, 0.1 ml of each serum
was used. Following electrophoresis, gels were placed in tubes containing 0.3%
dopa in 0.1 M phosphate buffer, pH 6.9, and incubated in a 370C water bath
for 2 hr. Gels were then washed in 7% acetic acid and scanned with a spectro-
photometer at 400 nm. The area under each dopa-positive peak was calculated
by planimetry.
RESULTS
Gel diffusion studies to demonstrate immunological reactivity between putative
tumor antigens in melanoma extracts and patient sera were not positive (17). Sera
collected serially from the two long-term immunotherapy patients and tested
against extracts of melanoma tumors, including those from which the vaccines were
prepared, did not demonstrate tumor antibody reactivity by gel diffusion. All mela-
noma tumor extracts, however, were found to have immunoglobulin G above the
level observed in corresponding normal tissues by immunodiffusion with specific
immunoglobulin antiserum. IgA was also demonstrated in a majority of tumor
extracts.
An eluate obtained from a tumor of a patient (T.C.) who had not received
prior systemic treatment was shown to contain IgG, while tumor eluate from the
patient (J.M) undergoing immunotherapy demonstrated both IgG and IgA. The
eluate (T.C.) containing only IgG had greater enhancing capacity than the eluate
with both immunoglobulins (Table 1). While melanoma tumor eluates enhanced
the growth of target cells, eluates from sarcoma tumor cells inhibited their growth.
An eluate prepared from normal muscle had little effect on cell growth.
Melanoma tumor extracts prepared by freeze-thaw cleavage were inhibitory to
cell growth. Tumor extracts prepared by fluorocarbon extraction were found to
TABLE 1
EFFECTS OF ELUATES AND EXTRACTS ON PLATED MELANOMA TARGET CELLS
Preparation Patient Tumor type % Enhancement % Inhibition
Eluate T.C. melanoma 400 none
Eluate J.M. melanoma (IT)c 116 none
Eluate F.B. sarcoma none 52
Eluate K.F. sarcoma none 43
Eluate S.C. normal muscle none 7
Extract N.M.a melanoma none 41
Extract L.R.a melanoma none 22
Extract A.C.a melanoma none 45
Extract C.H.b melanoma 122 none
Extract J.M.b melanoma (IT)c 120 none
a Extracts were prepared by freeze-thaw extraction 5 times.
b Extracts were prepared by Genetron 113 extraction for a total of 5 times.
c Immunotherapy patient.
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FIG. 1. Complement fixing antibody titers during immunotherapy. NV = new vaccine.
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FIG. 2. Complement fixing antibody titers during immunotherapy. NV= new vaccine;
R = recurrence of disease.
immunotherapy against a pool of melanoma tumors are shown in Charts 1 and
stimulate growth. The different effect is presumed to be owing to a higher concen-
tration of particulate protein in the freeze-thaw extracts than in the fluorocarbon
preparations, the latter containing only lipid-free soluble proteins. Sera from pa-
tients with melanoma usually stimulated the growth of cultured melanoma cells.
Complement-fixation titers of sera from each of the two patients undergoing
2. Patient M.I. (Fig. 1), after sporadic positive titers at the initiation of immuno-
therapy, had no titer some 5 months after immunotherapy was started. The titer
became positive 8 months later, but reverted to negative even with the introduction
of a new vaccine. It was still negative when recurrence of clinical disease was ob-
served 11 months later.
The second immunotherapy patient (J.M.) demonstrated complement-fixing
antibody during the initial period of his therapy regime (Fig. 2). The introduction
of a different vaccine may have been responsible for the disappearance of a comple-
ment-fixation titer. When another vaccine was subsequently utilized, however, his
titer again became elevated. Recurrence of clinical disease was observed while his
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TABLE 2
FREQUENCY OF LYMPHOCYTE CYTOTOXICITY ON MELANOMA TARGET CELLS
No. tested No. positive
Melanoma patients 4 3
Immunotherapy patients 2 0
Normal control donors 3 0
titer remained high. It may be relevant that a complement-fixation titer was not
registered during the time when both patients were receiving the same vaccine.
Cytotoxic antibody was not observed at any time during the course of immuno-
therapy when the sera were examined by the complement-dependent microcytotox-
icity tests. In fact, target cells appeared to thrive in the presence of patient serum
and complement. The growth of the target cells was slightly enhanced or not
affected by serum alone. Enhanced growth was presumed to be mediated by the
human cord serum used to dilute the rabbit complement.
Table 2 depicts the frequency of lymphocyte cytotoxicity to cultured melanoma
target cells observed in these tests. While three of four patients with untreated
melanoma had cytotoxic lymphocytes, they were not present in the two patients
following long-term immunotherapy. It is not known whether either immunother-
apy patient had cytotoxic lymphocytes before treatment. Results obtained from
studies on patient M.I.'s sera are shown in Fig. 3. There was no blocking activity
in his sera at the commencement of immunotherapy; he did, however, develop
blocking factors 5 months later which were maintained for 7 months. During this
period, there was no complement fixing antibody detected, and dopa-positive reac-
tions were near levels obtained with normal serum. Shortly after the blocking fac-
tors disappeared, there was a striking increase in dopa-positive activity concomitant
with a rise in complement-fixing antibody titer. The complement-fixation reactivity
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FIG. 4. Dopa-positive reactivity of sera from patient J.M. NV = new vaccine; R = recur-
rence of disease; C-F = complement fixing antibody.
then declined while the dopa-positive reactivity persisted up to the time when re-
current disease was clinically detectable.
Figure 4 depicts the results obtained in studies of patient J.M.'s serial serum
samples. Blocking activity and complement-fixing antibodies were present at first.
Blocking factors, however, disappeared after 6 months of therapy with the same
vaccine. The complement-fixing activity was lost after the administration of a new
vaccine preparation and remained absent until after the administration of a third
vaccine preparation. Thereafter, complement-fixing antibody levels maintained at
a high level and serum dopa-positive reactivity increased. Prolonged absence of
a complement-fixing antibody titer was observed during the administration of the
same vaccine preparation in both patients M.I. and J.M.
An eluate prepared from J.M.'s recurrent tumor mass following immunotherapy
was repeatedly found to completely block lymphocyte cytotoxicity and also to en-
hance the growth of melanoma target cells. An eluate similarly prepared from an
untreated melanoma patient had the capacity to block lymphocyte cytotoxicity by
80%; in the absence of lymphocytes, however, it had a greater enhancing ability
on target cell growth.
DISCUSSION
While gel diffusion studies have revealed the presence of specific immunoglobu-
lins in tumor extract preparations above that found in normal tissues., the biological
role of these proteins is not known. It seems plausible that these immunoglobulins
are associated with or function in response to some determinant on the tumor cell
membrane. In this respect, they may facilitate tumor cell growth by masking of
tumor specific membrane antigens and thereby protect cells from cytotoxic
lymphocytes.
Attempts to identify the function of these immunoglobulins requires that they
be isolated from other cellular products which may influence tumor target cells.
Consequently, the eluates, which primarily contain immunoglobulins, enhance
melanoma target cell growth, while less pure extracts of tumor tissue can inhibit
699700 ROMSDAHL AND COX
growth. The eluates contain immunoglobulin G, often IgA, and possibly dissociated
antigen. Extracts presumably contain antigen-antibody complexes in addition to
a myriad of proteins. The specificity of the eluates from melanoma tumors toward
melanoma target cells is supported by failure to show an enhancing effect with
either human sarcoma or muscle eluate preparations in the identical test system.
These preliminary observations do not permit one to consider which immuno-
globulin may play the more prominent role in enhancement. We did observe, how-
ever, that the eluate prepared from the patient undergoing immunotherapy blocked
the cytotoxic action of sensitized lymphocytes slightly more effectively than did
the eluate prepared from an untreated patient. The former contained both IgG
and IgA; the latter contained only IgG. Further experiments will be necessary in
an attempt to identify mechanisms operative in this relationship between cells and
immunoglobulins.
The complement-fixing antibody studies suggest that the host may well respond
to antigenic stimulation provided by the vaccine preparation, even though the lack
of specificity associated with this test precludes a correlation of titer to clinical
activity of the tumor in vivo. It may be noteworthy, however, that during periods
when complement-fixation titers were registered, serum dopa-oxidase reactivity was
prominent. Identification of a possible correlation between these has not yet been
shown.
Blocking of sensitized lymphocytes by sera from patients undergoing immuno-
therapy cannot in itself imply that the therapy is the causative factor. The demon-
stration of blocking was intermittent, though neither patient demonstrated blocking
activity during the year preceding the actual observance of recurrent disease. The
patients' own lymphocytes examined at this time were not sensitized to cultured
melanoma cells, and an eluate prepared from the tumor of one of the patients
was shown to effectively block sensitized lymphocyte cytotoxicity in an allogeneic
system.
It is now generally accepted that active immunotherapy has been of little, if
any, value. The possibility of enhancement of tumor growth in vivo is an ever-
present threat. Tumor growth may be facilitated through the elicitation of a
humoral response to melanoma vaccines which could result in serum-mediated
blocking of lymphocyte recognition and cytotoxicity. Tumor antigens in live cell
vaccines may also be masked from recognition by lymphocytes by an immuno-
globulin coating, thereby invoking a response to serum proteins in homologous
immunization or possibly a state of tolerance in the autologous situation.
If these mechanisms are real, methods could be sought first to remove such
immunoglobulins from tumor cells, then to use them for immunization to permit
antigen recognition by lymphocytes. Also, the humoral response to active immuni-
zation could be suppressed to prevent or modify the formation of blocking factors
responsible for abrogating lymphocyte cytotoxicity.
These considerations concerning the interaction of humoral and cellular immu-
nity in solid tumors may offer new approaches to the therapy of human malignant
melanoma.
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